Immuneering Corporation announced that it entered into an agreement to expand its existing relationship with Bristol-Myers Squibb for the use of Immuneering's proprietary computational biology methods to identify biological insights that may facilitate discovery and development of medicines. Immuneering's team of MIT-trained PhDs will perform advanced analyses on data from Bristol-Myers Squibb to derive new biological insights. Immuneering uses internally developed proprietary algorithms in combination with software licensed from leading research institutions.